Bicycle Therapeutics has patented a heterotandem bicyclic peptide complex for treating cancer. The complex binds to Nectin-4 and CD137, showing potential in preventing, suppressing, or treating cancer. The method involves administering the complex to patients, offering a promising approach in cancer therapy. GlobalData’s report on Bicycle Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Bicycle Therapeutics, Nanoparticle drug conjugates was a key innovation area identified from patents. Bicycle Therapeutics's grant share as of May 2024 was 13%. Grant share is based on the ratio of number of grants to total number of patents.
Treatment of cancer using heterotandem bicyclic peptide complex
A recently granted patent (Publication Number: US11970553B2) discloses a method for treating cancer in patients using a heterotandem bicyclic peptide complex. The complex comprises a first peptide ligand that binds to Nectin-4 and two second peptide ligands that bind to CD137. These ligands are conjugated via a specific linker and form covalent bonds with a molecular scaffold, creating two polypeptide loops. The method involves administering this complex, which can be in the form of a free acid or a pharmaceutically acceptable salt, to patients with various types of cancer.
The patent claims cover the treatment of a wide range of cancers, including carcinomas of the bladder, breast, gastrointestinal tract, lung, head and neck, ovary, and thyroid, among others. It also includes sarcomas of soft tissue, bone, or cartilage. The heterotandem bicyclic peptide complex can be administered alone or in combination with other pharmaceutically acceptable excipients. The method aims to provide a targeted approach to cancer treatment by utilizing the specific binding properties of the peptide ligands to inhibit tumor growth and progression effectively.
To know more about GlobalData’s detailed insights on Bicycle Therapeutics, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
